Copper deficiency as an anti-cancer strategy.

Copper is a tightly regulated trace element. Disruptions of copper homeostasis are rare and they cause serious disorders such as Wilson's disease and Menkes disease. Copper also plays an important role in promoting physiological and malignant angiogenesis. Formation of new blood vessels by a tumor enables tumor growth, invasion and metastasis. The copper chelator tetrathiomolybdate (TM), which quickly and effectively depletes copper stores, is under investigation as an anti-angiogenic agent. Promising results in vitro, in pre-clinical animal models and in an early (phase I) clinical trial have led to ongoing phase II evaluation of TM in patients with advanced cancers.

[1]  S. Merajver,et al.  Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. , 2003, Molecular cancer therapeutics.

[2]  R. Soldi,et al.  Copper chelation represses the vascular response to injury , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Merajver,et al.  Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  A. Bikfalvi,et al.  Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. , 2002, Trends in pharmacological sciences.

[5]  P. Bunn.  Molecular biology and early diagnosis in lung cancer. , 2002, Lung cancer.

[6]  F. Scappaticci.  Mechanisms and future directions for angiogenesis-based cancer therapies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Merajver,et al.  Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. , 2002, Cancer research.

[8]  T. K. Hunt,et al.  Copper-induced vascular endothelial growth factor expression and wound healing. , 2002, American journal of physiology. Heart and circulatory physiology.

[9]  D. Gomez,et al.  The copper‐chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells , 2001, International journal of cancer.

[10]  M. Key,et al.  Prevention of human prostate tumor metastasis in athymic mice by antisense targeting of human angiogenin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Igor Prudovsky,et al.  Copper Induces the Assembly of a Multiprotein Aggregate Implicated in the Release of Fibroblast Growth Factor 1 in Response to Stress* , 2001, The Journal of Biological Chemistry.

[12]  G. Brewer.  Copper Control as an Antiangiogenic Anticancer Therapy: Lessons from Treating Wilson's Disease , 2001, Experimental biology and medicine.

[13]  S. Merajver,et al.  The Role of Copper Suppression as an Antiangiogenic Strategy in Head and Neck Squamous Cell Carcinoma , 2001, The Laryngoscope.

[14]  Hernán Vásquez,et al.  Mineral composition of pastures in the North and Northwest regions of Rio de Janeiro State: 2. Manganese, iron, zinc, copper, cobalt, molybdenum and lead , 2000 .

[15]  H. Osiewacz,et al.  GRISEA, a copper-modulated transcription factor from Podospora anserina involved in senescence and morphogenesis, is an ortholog of MAC1 in Saccharomyces cerevisiae , 1998, Molecular and General Genetics MGG.

[16]  G. Hu.  Copper stimulates proliferation of human endothelial cells under culture , 1998, Journal of cellular biochemistry.

[17]  B. Vallee,et al.  Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Osiewacz,et al.  Mitochondrial DNA rearrangements of Podospora anserina are under the control of the nuclear gene grisea. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  F. Soncin,et al.  Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells. , 1997, Biochemical and biophysical research communications.

[20]  D. Kosman,et al.  Homeostatic Regulation of Copper Uptake in Yeast via Direct Binding of MAC1 Protein to Upstream Regulatory Sequences ofFRE1 and CTR1 * , 1997, The Journal of Biological Chemistry.

[21]  Harold E. Dvorak,et al.  Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors , 1997, Thrombosis and Haemostasis.

[22]  D. Thiele,et al.  Copper-specific Transcriptional Repression of Yeast Genes Encoding Critical Components in the Copper Transport Pathway* , 1997, The Journal of Biological Chemistry.

[23]  S. Fox,et al.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.

[24]  P. Hedera,et al.  Treatment of Wilson Disease With Ammonium Tetrathiomolybdate: III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy , 1996 .

[25]  U. Nuber,et al.  GRISEA, a putative copper-activated transcription factor fromPodospora anserina involved in differentiation and senescence , 1996, Molecular and General Genetics MGG.

[26]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[27]  P. Labbé,et al.  Evidence for the Saccharomyces cerevisiae Ferrireductase System Being a Multicomponent Electron Transport Chain* , 1996, The Journal of Biological Chemistry.

[28]  R. Hassett,et al.  Evidence for Cu(II) Reduction as a Component of Copper Uptake by Saccharomyces cerevisiae(*) , 1995, The Journal of Biological Chemistry.

[29]  R. Klausner,et al.  The Saccharomyces cerevisiae copper transport protein (Ctr1p). Biochemical characterization, regulation by copper, and physiologic role in copper uptake. , 1994, The Journal of biological chemistry.

[30]  M. Toi,et al.  Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer , 1994, Japanese journal of cancer research : Gann.

[31]  B. Vallee,et al.  A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. , 1994, Cancer research.

[32]  L. Bendell-Young,et al.  Metal concentrations in chrionomids in relation to peatland geochemistry , 1994 .

[33]  A. Aisen,et al.  Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. , 1994, Archives of neurology.

[34]  J. Peppercorn,et al.  The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene , 1993, Nature Genetics.

[35]  J. Rommens,et al.  The Wilson disease gene is a putative copper transporting P–type ATPase similar to the Menkes gene , 1993, Nature Genetics.

[36]  J. Gitlin,et al.  Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. , 1993, Biochemical and biophysical research communications.

[37]  C. Cordon-Cardo,et al.  Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. , 1993, Journal of the National Cancer Institute.

[38]  S. Brem,et al.  Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. , 1990, The American journal of pathology.

[39]  T. Watanabe,et al.  Molecular characterization of recombinant human acidic fibroblast growth factor produced in E. coli: comparative studies with human basic fibroblast growth factor. , 1990, Molecular endocrinology.

[40]  S. Brem,et al.  Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain. , 1990, Neurosurgery.

[41]  F. Soncin,et al.  Specific binding of angiogenin to calf pulmonary artery endothelial cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Rybak,et al.  Angiogenin mRNA in human tumor and normal cells. , 1987, Biochemical and biophysical research communications.

[43]  A. Aisen,et al.  Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. , 1987, Archives of neurology.

[44]  A. Young,et al.  Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. , 1987, Archives of neurology.

[45]  J. L. Bethune,et al.  Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. , 1985, Biochemistry.

[46]  P. Gullino,et al.  Angiogenesis in vivo and selective mobilization of capillary endothelium in vitro by heparin-copper complex. , 1984, Microcirculation, endothelium, and lymphatics.

[47]  G. Gole,et al.  Angiogenic factors and their assay: activity of formyl methionyl leucyl phenylalanine, adenosine diphosphate, heparin, copper, and bovine endothelium stimulating factor. , 1983, Microvascular research.

[48]  P. Gullino,et al.  Ceruloplasmin, copper ions, and angiogenesis. , 1982, Journal of the National Cancer Institute.

[49]  P. Gullino,et al.  Role of prostaglandin E1 and copper in angiogenesis. , 1982, Journal of the National Cancer Institute.

[50]  J. Walshe.  TREATMENT OF WILSON'S DISEASE WITH TRIENTINE (TRIETHYLENE TETRAMINE) DIHYDROCHLORIDE , 1982, The Lancet.

[51]  R. Cousins,et al.  Regulation of intestinal metallothionein biosynthesis in rats by dietary zinc. , 1981, The Journal of nutrition.

[52]  J. Folkman,et al.  Proceedings: Tumor angiogenesis factor. , 1974, Cancer research.

[53]  Neil Blumberg,et al.  Tumor Angiogenesis Factor , 1974, The Yale journal of biology and medicine.

[54]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[55]  J. Walshe.  Penicillamine, a new oral therapy for Wilson's disease. , 1956, The American journal of medicine.

[56]  J. Clarke,et al.  Medicine , 1907, Bristol medico-chirurgical journal.

[57]  S. Merajver,et al.  Radiotherapy and antiangiogenic TM in lung cancer. , 2002, Neoplasia.

[58]  M. Harada,et al.  Wilson disease , 2002, Medical Electron Microscopy.

[59]  G. Brewer.  The Clinician’s Challenge: Recognizing Wilson’s Disease , 2001 .

[60]  B. Neustadt,et al.  Inhibition of Angiogenesis and Tumor Growth by Sch221153, a Dual ␣ V ␤ 3 and ␣ V ␤ 5 Integrin Receptor Antagonist , 2022 .

[61]  S. Merajver,et al.  Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  M. I. Kudashkin.  The content of different copper compounds in the gray forest soils of Mordovia and the effectiveness of the treatment of barley seeds with copper sulfate before planting , 2000 .

[63]  D. Winge.  Copper-regulatory domain involved in gene expression. , 1999, Advances in experimental medicine and biology.

[64]  J. Mercer,et al.  Copper transport and its disorders : molecular and cellular aspects , 1999 .

[65]  J. Brunberg,et al.  Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. , 1996, Archives of neurology.

[66]  R. Cousins,et al.  Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. , 1992, The Journal of laboratory and clinical medicine.

[67]  A. Young,et al.  Initial therapy of patients with Wilson's disease with tetrathiomolybdate. , 1991, Archives of neurology.

[68]  R. Palmer,et al.  Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea. , 1988, The American journal of pathology.

[69]  L. E. Scott,et al.  Copper regulation of ceruloplasmin in copper-deficient rats. , 1979, Enzyme.

[70]  A. C. Hall,et al.  Intestinal metallothionein and the mutual antagonism between copper and zinc in the rat. , 1979, Journal of inorganic biochemistry.